Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Makers Must Continue AMP Medicaid Calculations, Despite Court Ruling

This article was originally published in The Pink Sheet Daily

Executive Summary

Dec. 19 federal court injunction bars CMS from publishing AMP data for now.

You may also be interested in...



Medicaid AMP: Manufacturers Have Reason To Hope For Significant Changes In Final Rule

A major regulation that could reshape how the pharmaceutical industry reports drug pricing to the government and pays rebates on Medicaid drugs is slated to be released in final form in 2014. Some Medicaid regulatory experts suggest that CMS could make changes in the final rule that will make it less disruptive to manufacturers’ businesses than they have feared.

CMS Makes Headway Toward Part B Drug Price Substitutions

CMS might finally be able to use the Medicare Part B drug price substitution authority provided in the Medicare Modernization Act of 2003, due to the combined effect of the recent redefinition of average manufacturer price for drugs and the proposed Medicare physician fee schedule rule for 2011

CMS Makes Headway Toward Part B Drug Price Substitutions

CMS might finally be able to use the Medicare Part B drug price substitution authority provided in the Medicare Modernization Act of 2003, due to the combined effect of the recent redefinition of average manufacturer price for drugs and the proposed Medicare physician fee schedule rule for 2011

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel